Skip to main content

Table 5 Interrupted time series analysis of the use of broad-spectrum antibiotics in defined daily doses per 100 bed days for intervention and control groups from 2013 to 2015

From: The effect of antibiotic stewardship interventions with stakeholder involvement in hospital settings: a multicentre, cluster randomized controlled intervention study

 

Audit with feedback (Intervention wards)

Academic detailing (Intervention wards

Pulmonary medicine (Intervention wards)

Infectious diseases (Intervention wards)

Gastroenterology (Intervention ward)

Control (all specialties)

Estimate

SE

p-value

Estimate

SE

p-value

Estimate

SE

p-value

Estimate

SE

p-value

Estimate

SE

p-value

Estimate

SE

p-value

DDD per 100 bed days

Const

70.288

5.854

0.000

103.078

8.415

0.000

84.736

5.056

0.000

60.371

7.407

0.000

27.605

1.592

0.000

87.691

5.387

0.000

AR

−0.495

0.326

0.172

−0.247

0.370

0.525

−0.429

0.348

0.257

−0.239

0.372

0.542

−0.796

0.203

0.006

−0.512

0.323

0.157

Pre-slope

 

4.332

1.523

0.025

−2.903

2.181

0.225

−2.292

1.312

0.124

3.985

1.926

0.077

−0.075

0.411

0.861

1.002

1.404

0.498

Difference between pre- and post-slope

 

−6.789

2.028

0.012

2.920

2.985

0.360

−0.669

1.770

0.717

−5.753

2.615

0.064

2.472

0.545

0.003

−1.033

1.863

0.597

Level effect

 3 months

 

−8.971

7.809

0.288

−3.162

11.053

0.783

8.314

6.686

0.254

−10.360

9.839

0.327

−11.157

2.082

0.001

1.407

7.191

0.850

 6 months

 

−15.761

8.313

0.100

−0.242

11.823

0.984

7.646

7.131

0.319

−16.112

10.503

0.169

−8.685

2.220

0.006

0.374

7.672

0.962

 12 months

 

−29.338

10.490

0.027

5.599

15.115

0.722

6.308

9.052

0.508

−27.617

13.357

0.077

−3.740

2.811

0.225

−1.691

9.694

0.866

 18 months

 

−42.916

13.561

0.016

11.439

19.708

0.580

4.971

11.751

0.685

−39.122

17.355

0.059

1.205

3.640

0.750

−3.757

12.525

0.773

  1. Broad-spectrum antibiotics were defined as penicillins with enzyme inhibitor, 2. and 3. generation cephalosporins, carbapenems and quionolones